SCHEMBL14320640

SCHEMBL14320640

c1csc(-c2nc(Nc3ccc(-n4nccn4)cc3)c3[nH]ncc3n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.46
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 5/20 0.43
MAPT P10636 5/20 0.43
GBA1 P04062 4/20 0.43
LMNA P02545 3/20 0.43
HTT P42858 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM1A O60341 1/20 0.43
ABCG2 Q9UNQ0 6/20 0.41
ABCB1 P08183 2/20 0.39
ABCC1 P33527 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4D Q08499 1/20 0.37
ADORA3 P0DMS8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320370 0.89 ABCG2 (0.46) PDE5AMEN1KMT2AKDM4EALDH1A1
SCHEMBL14320401 0.83 SYK (0.55) PDE5AMEN1KMT2AKDM4EALDH1A1
SCHEMBL14320738 0.83 PDE5A (0.44) PDE5AMEN1KMT2AKDM4EALDH1A1
SCHEMBL14321176 0.83 FLT3 (0.53) PDE5AMEN1KMT2AKDM4EALDH1A1
SCHEMBL27932744 0.82 MEN1 (0.52) PDE5AMEN1KMT2AKDM4EALDH1A1
SCHEMBL14320815 0.81 PDGFRB (0.45) PDE5AMEN1KMT2AKDM4EALDH1A1
SCHEMBL13737153 0.81 PDE5A (0.48) PDE5AMEN1KMT2AKDM4EALDH1A1
SCHEMBL14320409 0.81 KDM1A (0.66) PDE5AMEN1KMT2AKDM4EALDH1A1
SCHEMBL14321185 0.80 SYK (0.42) PDE5AKDM4EALDH1A1MAPTGBA1
SCHEMBL13735957 0.80 FLT3 (0.43) PDE5AMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK PDE5A 1895/4885MEN1 544/4885KMT2A 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.